pirfenidone has been researched along with Colitis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, G; Deng, Y; Gu, G; Guo, K; Hu, Q; Li, G; Li, J; Li, R; Li, Y; Ren, J; Wang, G; Wu, L | 1 |
Chilvers, ER; Fiddler, CA; Miremadi, A; Parfrey, H; Simler, N | 1 |
2 other study(ies) available for pirfenidone and Colitis
Article | Year |
---|---|
Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model.
Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Proliferation; Cell Survival; Colitis; Collagen; Colon; Disease Models, Animal; Female; Fibrosis; Gastrointestinal Agents; Humans; Intestinal Mucosa; Mice, Inbred C57BL; Pyridones; Random Allocation; Signal Transduction; Specific Pathogen-Free Organisms; Transforming Growth Factor beta | 2016 |
Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones | 2016 |